Cargando…

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

BACKGROUND: This study aimed to propose a new user-friendly, cost effective and robust risk model to facilitate risk stratification for diffuse large B-cell lymphoma (DLBCL) treated with frontline R-CHOP regimens. METHODS: Data on 998 patients with de novo DLBCL diagnosed between Jan 1st, 2005 and D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Haizhu, Zhong, Qiaofeng, Zhou, Yu, Qin, Yan, Yang, Jianliang, Liu, Peng, He, Xiaohui, Zhou, Shengyu, Zhang, Changgong, Gui, Lin, Yang, Sheng, Zhou, Liqiang, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137167/ https://www.ncbi.nlm.nih.gov/pubmed/35624433 http://dx.doi.org/10.1186/s12885-022-09693-z

Ejemplares similares

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era
por: Wang, Qin, et al.
Publicado: (2016)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
por: Shi, Yuankai, et al.
Publicado: (2015)

Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type
por: Dai, Wumin, et al.
Publicado: (2017)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kang, Jihoon, et al.
Publicado: (2017)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
por: Shi, Yuankai, et al.
Publicado: (2019)

Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis
por: Zhou, Yu, et al.
Publicado: (2021)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era
por: Ho, Ching-Liang, et al.
Publicado: (2015)

Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
por: Huang, Yu, et al.
Publicado: (2017)

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy
por: Zhou, Yu, et al.
Publicado: (2021)

Prognostic values of red blood cell distribution width, platelet count, and red cell distribution width-to-platelet ratio for severe burn injury
por: Qiu, Le, et al.
Publicado: (2017)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma
por: Shang, Yufeng, et al.
Publicado: (2018)

Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2021)

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
por: Qin, Yan, et al.
Publicado: (2020)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis
por: Jiang, Tiantong, et al.
Publicado: (2016)

The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer
por: Takeuchi, Hideya, et al.
Publicado: (2017)

A Nomogram to Predict Prognostic Value of Red Cell Distribution Width in Patients with Esophageal Cancer
por: Chen, Gui-Ping, et al.
Publicado: (2015)

The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020
por: Zhong, Qiaofeng, et al.
Publicado: (2021)

Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis.
por: Child, J. A., et al.
Publicado: (1983)

A prognostic nomogram incorporating red cell distribution width for patients with intracerebral hemorrhage
por: Cui, Zhe, et al.
Publicado: (2020)

Prognostic Significance of CD276 in Non-small Cell Lung Cancer
por: Zhang, Changgong, et al.
Publicado: (2019)

Red cell distribution width—a potential prognostic indicator for colorectal cancer patients after radical resection in China
por: Zhao, Weiwei, et al.
Publicado: (2023)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Prognostic significance of red blood cell distribution width in gastrointestinal cancers: A meta-analysis
por: Zhou, Yongping, et al.
Publicado: (2020)

Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients
por: Zhou, Shujuan, et al.
Publicado: (2017)

Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients
por: Li, Manman, et al.
Publicado: (2019)

Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor
por: Yoo, Changhoon, et al.
Publicado: (2014)

Clinical and prognostic significance of perioperative change in red cell distribution width in patients with esophageal squamous cell carcinoma
por: Zhang, Peng, et al.
Publicado: (2023)

The Red Blood Cell Distribution Width–Albumin Ratio Was a Potential Prognostic Biomarker for Diabetic Ketoacidosis
por: Zhou, Depu, et al.
Publicado: (2021)

Prognostic significance of red cell distribution width in bladder cancer
por: Ma, Wenchao, et al.
Publicado: (2020)

Is red blood cell distribution width a prognostic factor for colorectal cancer? A meta-analysis
por: Wen, Ze-Lin, et al.
Publicado: (2022)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B‐cell lymphoma in the rituximab era
por: Ishikawa, Eri, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lbap4ljufrm7ng31bbd2b0emsr